Skip to main content
. 2016 Aug 13;7(38):61166–61182. doi: 10.18632/oncotarget.11278

Figure 3. FRS2 was up-regulated in recurrent/metastatic lesions, compared to their matched primary lesions in tamoxifen-resistant patients.

Figure 3

(A) FRS2 expression was compared between paired primary and recurrent/metastatic (R/M) lesions of 9 patients who relapsed after TAM therapy using immunohistochemistry (IHC). M-score was used to estimate FRS2 expression. Fold change was calculated as the mean ratio of M-score in R/M lesions to matched primary lesions. P values were calculated using paired two-sided t-test. The IHC staining results of (B) the primary and (C) R/M lesions from Patient SICK0000538 were showed (100X), with an M-score of 33.33 and 41.67, respectively.